EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONT ...
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1179
https://www.valueinhealthjournal.com/article/S1098-3015(15)01236-X/fulltext
Title :
EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONT ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01236-X&doi=10.1016/j.jval.2015.03.1179
First page :
A307
Section Title :
Cancer
Open access? :
No
Section Order :
1274